#USA #New York #Elacestrant #Menarini Group #ASCO 2026

Menarini Group Unveils Innovative Clinical Data at ASCO 2026

Menarini Group, a leading international pharmaceutical and diagnostics company, made a significant announcement at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2026, showcasing groundbreaking data on several cancer therapies. This year’s presentations spanned across seven pivotal studies involving both hematological neoplasms and solid tumors, demonstrating the potential benefits of new treatment approaches for patients grappling with advanced cancer.

The highlight of Menarini's presentations was the updated findings from the ELEVATE study, which examined the combination of elacestrant and capivasertib. This groundbreaking research focused on metastatic breast cancer (mBC) patients and provided insights into the efficacy of these therapies, particularly in combination with others. The results showed promising outcomes for patients with ER+/HER2- breast cancer alterations, underscoring elacestrant's potential role as part of a combined treatment strategy, alongside additional agents such as everolimus.

Moreover, the company shared exciting updates regarding the ongoing clinical development of elacestrant as a standalone therapy in the adjuvant setting for early-stage breast cancer. Through these results, Menarini aims to address the urgent need for innovative solutions in complex cases where current treatments fall short.

In addition to elacestrant, new data related to tagraxofusp were also presented, focusing on its efficacy for patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This data was presented by Dr. Naveen Pemmaraju from the prestigious MD Anderson Cancer Center.

The company’s partner, Karyopharm Therapeutics, contributed to the momentum of the discussions with a late-breaking oral presentation regarding the phase 3 SENTRY trial of selinexor in patients with primary myelofibrosis. This data further illustrates the commitment of Menarini and Stemline Therapeutics to impactful cancer therapies aimed at transforming patient outcomes.

In a statement from Elcin Barker Ergun, CEO of Menarini Group, he remarked, "The extensive oncology data being presented highlights our commitment to addressing some of the toughest-to-treat cancers that remain unmet. We remain dedicated to accelerating innovation to provide transformative therapies that offer meaningful improvements for patients and to those involved in their care."

Key Presentations from ASCO 2026

Menarini's robust agenda for the ASCO 2026 included several noteworthy presentations:

• - Elacestrant in Combination with Capivasertib: Investigated under the ELEVATE study, showcasing updated findings for advanced ER+/HER2- breast cancer patients.
• - ELEGANT Study: A randomized, multicentric study assessing elacestrant against standard endocrine therapy in hormone-positive early-stage breast cancer.
• - ADELA Study: Evaluated the combination of elacestrant with everolimus in patients with advanced ER+/HER2- tumors.
• - CAPELA Study: Focused on evaluating elacestrant combined with capecitabine versus capecitabine alone.
• - Tagraxofusp for BPDCN: This phase 2 trial provided significant insights into treating this aggressive hematological malignancy.
• - Selinexor in Myelofibrosis: Presented new therapeutic options for patients previously untreated with JAK inhibitors.

Conclusion

Menarini Group's announcements at ASCO 2026 signify a pivotal moment in oncology with advances that may change the treatment landscape for patients suffering from various forms of cancer. By continuing to explore the intersections of innovative therapies and setting the foundation for future studies, Menarini underscores its ongoing commitment to the field of oncology, ensuring that patients have access to transformative and much-needed therapies. As research continues, stakeholders can look forward to further updates that promise to evolve cancer treatment paradigms across the board.